MDGL - シンタ・ファ―マシュ―ティカルズ (Madrigal Pharmaceuticals Inc.) シンタ・ファ―マシュ―ティカルズ

 MDGLのチャート


 MDGLの企業情報

symbol MDGL
会社名 Madrigal Pharmaceuticals Inc (シンタ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マドリガル・ファーマシューティカルズ(Madrigal Pharmaceuticals Inc)(旧名:Synta Pharmaceuticals Corp.)は臨床病期のバイオ医薬品会社である。同社は心血管代謝疾患および非アルコール性脂肪性肝炎(NASH)の治療用の治療候補の開発・商業化に従事する。主力製品であるMGL-3196は、NASHの治療用第Ⅱ相準備の1日1回、経口、肝臓特異的選択甲状腺ホルモン受容体-b(THR-b)アゴニスト、および異型接合性および同型接合性家族性高コレステロール血症(FH)である。その製品パイプラインには、NASHとFHの治療に使用されるMGL-3745も含まれる。MGL-3196は、健康なボランティアで第I相単回投与および複数回投与試験を完了し、低密度リポタンパク質コレステロール、トリグリセリドレベルおよびリポタンパク質(a)を低下させるための異常脂質血症/高コレステロール血症のために開発されている。また、脂肪代謝を増加させることによって血漿・肝臓中のトリグリセリドを減少させ、抗糖尿病作用を示す。   シンタ・ファ―マシュ―ティカルズは米国のバイオ医薬品メ―カ―。主にがんや慢性炎症性疾患などの、重篤な病状や患者のための小分子薬の発見・開発・製品化に取り組む。臨床段階のがんの候補薬や、前臨床段階の炎症性疾患治療薬の開発プログラムを保有する。本社はマサチュ―セッツ州レキシントン。   
本社所在地 Four Tower Bridge 200 Barr Harbor Drive Suite 400 West Conshohocken PA 19428 USA
代表者氏名 Paul A. Friedman ポール・A・フリードマン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 404-380-9263
設立年月日 36586
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 8人
url www.syntapharma.com
nasdaq_url https://www.nasdaq.com/symbol/mdgl
adr_tso
EBITDA EBITDA(百万ドル) -32.32700
終値(lastsale) 199.3138
時価総額(marketcap) 3062782215.7492
時価総額 時価総額(百万ドル) 2957.77
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 2467.465
当期純利益 当期純利益(百万ドル) -29.63200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Madrigal Pharmaceuticals Inc revenues was not reported. Net loss decreased 11% to $12.8M. Lower net loss reflects Interest income increase from $168K to $1.9M (income) Research and development decrease of 16% to $9.2M (expense) General and administrative decrease of 2% to $2.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.20 to -$0.90.

 MDGLのテクニカル分析


 MDGLのニュース

   Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/03/04 15:26:33 Investing.com
Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Madrigal Pharmaceuticals Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/02/23 14:56:00 Stock Market Daily
Madrigal Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   So Microcap Biotechs Is Where The Action Is Next...  2021/02/04 23:59:00 Zero Hedge
So Microcap Biotechs Is Where The Action Is Next… Earlier today we observed that just as the Gamestop short squeeze was finally fizzling with the buying frenzy turning to full-blown liquidation, which sent GME stock below $50 or down nearly 50% on the day... ... back to where it was trading on the Friday when Andrew Left capitulated to the r/wallstreetbets horde, a clear rotation was taking place, one which we last Friday predicted would take place... What's after the short squeeze slaughter: the pennystock pump? — zerohedge (@zerohedge) January 30, 2021 .... namely one out of the " most-shorted" names and into the "most-illiquid", microcap stocks as shown below. And while the waves of ramping were initially diffuse without a clear target, as the day progressed it emerged that the " reddit rebellion" was now targeting tiny biotech names (under $2 billion in market cap, hence illiquid enough where a group of retail daytraders could leave quite a mark) which while not having GME's absurd 140% short-to-float ratio were also quite shorted.
   B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/01/12 20:35:57 Investing.com
B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc  2020/11/12 11:18:10 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/03/04 15:26:33 Investing.com
Leerink Partners Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Madrigal Pharmaceuticals Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/02/23 14:56:00 Stock Market Daily
Madrigal Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   So Microcap Biotechs Is Where The Action Is Next...  2021/02/04 23:59:00 Zero Hedge
So Microcap Biotechs Is Where The Action Is Next… Earlier today we observed that just as the Gamestop short squeeze was finally fizzling with the buying frenzy turning to full-blown liquidation, which sent GME stock below $50 or down nearly 50% on the day... ... back to where it was trading on the Friday when Andrew Left capitulated to the r/wallstreetbets horde, a clear rotation was taking place, one which we last Friday predicted would take place... What's after the short squeeze slaughter: the pennystock pump? — zerohedge (@zerohedge) January 30, 2021 .... namely one out of the " most-shorted" names and into the "most-illiquid", microcap stocks as shown below. And while the waves of ramping were initially diffuse without a clear target, as the day progressed it emerged that the " reddit rebellion" was now targeting tiny biotech names (under $2 billion in market cap, hence illiquid enough where a group of retail daytraders could leave quite a mark) which while not having GME's absurd 140% short-to-float ratio were also quite shorted.
   B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/01/12 20:35:57 Investing.com
B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc  2020/11/12 11:18:10 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   So Microcap Biotechs Is Where The Action Is Next...  2021/02/04 23:59:00 Zero Hedge
So Microcap Biotechs Is Where The Action Is Next… Earlier today we observed that just as the Gamestop short squeeze was finally fizzling with the buying frenzy turning to full-blown liquidation, which sent GME stock below $50 or down nearly 50% on the day... ... back to where it was trading on the Friday when Andrew Left capitulated to the r/wallstreetbets horde, a clear rotation was taking place, one which we last Friday predicted would take place... What's after the short squeeze slaughter: the pennystock pump? — zerohedge (@zerohedge) January 30, 2021 .... namely one out of the " most-shorted" names and into the "most-illiquid", microcap stocks as shown below. And while the waves of ramping were initially diffuse without a clear target, as the day progressed it emerged that the " reddit rebellion" was now targeting tiny biotech names (under $2 billion in market cap, hence illiquid enough where a group of retail daytraders could leave quite a mark) which while not having GME's absurd 140% short-to-float ratio were also quite shorted.
   B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc By Investing.com  2021/01/12 20:35:57 Investing.com
B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc  2020/11/12 11:18:10 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
   The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping  2020/11/05 12:54:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
   Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights - Stocks News Feed  2020/11/05 11:50:00 Stocks News Feed
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also announced its third quarter 2020 financial results and highlights. The original target enrollment for MAESTRO… Read More »Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 シンタ・ファ―マシュ―ティカルズ MDGL Madrigal Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)